Eli Lilly's Zepbound Shows Promise in Treating Sleep Apnea and Obesity

Recent studies reveal that Zepbound not only aids in significant weight loss but also reduces sleep apnea symptoms, potentially expanding its medical applications.

Zepbound, a weight loss drug by Eli Lilly, demonstrated up to 63% reduction in sleep apnea symptoms in recent trials.
The drug, also known as tirzepatide, helped patients lose an average of 18% to 20% of their body weight over a year.
Eli Lilly plans to seek FDA approval for Zepbound to treat sleep apnea, aiming for broader insurance coverage including Medicare.
Studies indicate that Zepbound could be the first pharmaceutical treatment targeting the underlying disease of sleep apnea.
High demand for weight loss drugs like Zepbound has led to shortages, affecting supply chains and patient access.